Telomerase: a target for cancer therapeutics.
The continuous growth of advanced malignancies almost universally correlates with the reactivation of telomerase. While there is still a great deal of basic and applied research to be done, telomerase remains a very attractive novel target for cancer therapeutics. In this review, we will discuss the challenges and the pros and cons of the most promising antitelomerase approaches currently being investigated.
Shay
Jerry W
JW
The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75309, USA. jerry.shay@utsouthwestern.edu
Wright
Woodring E
WE
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy; D008954:Models, Biological; D009369:Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D016337:RNA, Catalytic / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D016615:Telomere / Q000737:chemistry / Q000378:metabolism
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D018894:Reverse Transcriptase Inhibitors; D019098:Telomerase